NETRI

NETRI’s main challenge is to overcome the failure of translating animal models, whose results often do not match human biology, thereby creating unmet medical needs. This issue is critical in a context where nearly 90% of clinical trials fail, with 50% due to lack of efficacy.

To establish itself, the startup must achieve broad regulatory acceptance from organizations such as the FDA and the EMA, while demonstrating the perfect reproducibility of its technology through multi-site testing with major pharmaceutical partners.

The ultimate challenge lies in accurately predicting clinical trial outcomes in order to reduce these high failure rates and address a drug development process that currently takes around 15 years and costs approximately $2 billion per drug.

NETRI’s innovation is based on the use of its methology “Neurons as a sensor” capable of translating preclinical data into clinical outcomes.

By isolating the nervous system within their hardware device, “NeoBento” (a standardized 96-well format), they record digital signatures of drug interactions.

These signatures are then analyzed using artificial intelligence and compared to a reference library of compounds to predict whether a treatment will be effective or toxic, even before human testing begins, thereby helping reduce the high clinical failure rates observed today.

NETRI aims to accelerate patient access to treatments by reducing drug development timelines, directly contributing to:

• SDG 3 - Good Health and Well-being: Their technology enhances safety by more accurately identifying side effects such as neurotoxicity or immune reactions, which traditional animal models often fail to detect, while also driving innovation in pharmaceutical research in line with
• SDG 9 - Industry, Innovation and Infrastructure: In the long term, the startup seeks to enable personalized medicine, allowing hospitals to test drug effectiveness directly on a patient’s own cells.
• SDG 17 - Partnerships for the Goals: fostering collaboration across healthcare ecosystems, supporting.

The 3DEXPERIENCE platform is central to NETRI’s industrial strategy, helping modernize its entire manufacturing process. It also supports the management of their digital library system, which stores and organizes compound signatures used for predictive analysis, contributing to more efficient and scalable drug development.

NETRI’s growth strategy relies on close collaboration with major pharmaceutical companies to validate the robustness of its methodology through cross-testing.

The company adopts a technology licensing model, enabling its tools to be widely used in laboratories and potentially reducing the industry’s high failure rates.

Its system is designed to be open and complementary, capable of integrating complex biological architectures, such as organoids, developed by other industry partners.